Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity

Journal of Allergy and Clinical Immunology

Volumn 116, Issue 2, 2005, Pages 347-354

  Reisinger, Jürgen ^a   Horak, Friedrich ^a   Pauli, Gabrielle ^c   Van Hage, Marianne ^b   Cromwell, Oliver ^d   König, Franz ^a   Valenta, Rudolf ^a   Niederberger, Verena ^a,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d ALLERGOPHARMA JOACHIM GANZER KG   (Germany)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergen specific immunotherapy; Genetically modified allergens; IgG antibodies; Nasal provocation

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; PLACEBO; POLLEN ANTIGEN; RECOMBINANT ANTIGEN; RECOMBINANT BIRCH POLLEN ALLERGEN; UNCLASSIFIED DRUG;

ADULT; ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BIRCH; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MODIFICATION; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALE; NOSE PROVOCATION TEST; NOSE SECRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOMANOMETRY; SEASONAL VARIATION; VACCINATION;

ADULT; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NASAL MUCOSA; PLANT PROTEINS; RECOMBINANT PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 23244437462     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2005.04.003     Document Type: Article

References (26)

1. R. Valenta, and D. Kraft From allergen structure to new forms of allergen-specific immunotherapy Curr Opin Immunol 14 2002 718 727
2. R. Hiller, S. Laffer, C. Harwanegg, M. Huber, W.M. Schmidt, and A. Twardosz Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment FASEB J 16 2002 414 416
3. R. Valenta The future of antigen-specific immunotherapy of allergy Nat Rev Immunol 2 2002 446 453
4. M.B. Singh, N. de Weerd, and P.L. Bhalla Genetically engineered plant allergens with reduced anaphylactic activity Int Arch Allergy Immunol 119 1999 75 85
5. F. Ferreira, M. Wallner, H. Breiteneder, A. Hartl, J. Thalhammer, and C. Ebner Genetic engineering of allergens: future therapeutic products Int Arch Allergy Immunol 128 2002 171 178
6. S. Vrtala, M. Focke-Tejkl, I. Swoboda, D. Kraft, and R. Valenta Strategies for converting allergens into hypoallergenic vaccine candidates Methods 32 2004 313 320
7. A.C. Drew, N.P. Eusebius, L. Kenins, H.D. de Silva, C. Suphioglu, and J.M. Rollan Hypoallergenic variants of the major latex allergen Hev b 6 retaining human T lymphocyte reactivity J Immunol 173 2004 5872 5879
8. V. Niederberger, F. Horak, S. Vrtala, S. Spitzauer, M.T. Krauth, and P. Valent Development of a novel allergy vaccine: genetically engineered allergens prevent progression of allergic disease Proc Nat Acad Sci U S A 101 suppl 2 2004 14677 14682
9. S. Vrtala, K. Hirtenlehner, L. Vangelista, A. Pastore, H.G. Eichler, and W.R. Sperr Conversion of the major birch pollen allergen, Bet v 1 into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy J Clin Invest 99 1997 1673 1681
10. S. Vrtala, K. Hirtenlehner, M. Susani, M. Akdis, F. Kussebi, and C.A. Akdis Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1 FASEB J 15 2001 2045 2047 (Express article Available at: www.fasebj.org/cgi/reprint/00-0767fjev1 )
11. G. Pauli, A. Purohit, J.P. Oster, F. De Blay, S. Vrtala, and V. Niederberger Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population Clin Exp Allergy 30 2000 1076 1084
12. M. van Hage-Hamsten, M. Kronqvist, O. Zetterstrom, E. Johansson, V. Niederberger, and S. Vrtala Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season J Allergy Clin Immunol 104 1999 969 977
13. F.D. Ferreira, K. Hoffmann-Sommergruber, H. Breiteneder, K. Pettenburger, C. Ebner, and W. Sommergruber Purification and characterization of recombinant Bet v 1, the major birch pollen allergen: immunological equivalence to natural Bet v 1 J Biol Chem 268 1993 19574 19580
14. V. Mahler, S. Vrtala, O. Kuss, T.L. Diepgen, R. Suck, and O. Cromwell Vaccines for birch pollen allergy based on genetically-engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1 Clin Exp Allergy 34 2004 510 512
15. S. Vrtala, M. Susani, W.R. Sperr, P. Valent, S. Laffer, and C. Dolecek Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p 2, Phl p 5) J Allergy Clin Immunol 97 1996 781 787
16. S. Denepoux, P.B. Eibensteiner, P. Steinberger, S. Vrtala, V. Visco, and A. Weyer Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1: anti-allergen IgG can enhance the anaphylactic reaction FEBS Lett 465 2000 39 46
17. S. Vrtala, C.A. Akdis, F. Budak, M. Akdis, K. Blaser, and D. Kraft T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies J Immunol 165 2000 6653 6659
18. K. Hoffmann-Sommergruber, E.D. Ferreira, C. Ebner, T. Barisani, L. Korninger, and D. Kraft Detection of allergen-specific IgE in tears of grass pollen-allergic patients with allergic rhinoconjunctivitis Clin Exp Allergy 26 1996 79 87
19. R. Aghayan-Ugurluoglu, T. Ball, S. Vrtala, C. Schweiger, D. Kraft, and R. Valenta Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens J Allergy Clin Immunol 105 2000 803 813
20. S. Flicker, and R. Valenta Renaissance of the blocking antibody concept in type I allergy Int Arch Allergy Immunol 132 2003 13 24
21. N. Mothes, M. Heinzkill, K.J. Drachenberg, W.R. Sperr, M.T. Krauth, and Y. Majlesi Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted IgE production and inhibition of basophil histamine release by therapy-induced blocking antibodies Clin Exp Allergy 33 2003 1 11
22. T. Ball, W.R. Sperr, P. Valent, J. Lidholm, S. Spitzauer, and C. Ebner Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy Eur J Immunol 29 1999 2026 2036
23. P.M. Clinton, D.M. Kemeny, L.J. Youlten, and M.H. Lessof Histamine release from peripheral blood leukocytes with purified bee venom allergens: effect of hyperimmune beekeeper plasma Int Arch Allergy Immunol 89 1989 43 48
24. P.A. Wachholz, and S.R. Durham Mechanisms of immunotherapy: IgG revisited Curr Opin Allergy Clin Immunol 4 2004 313 318
25. P.A. Wachholz, N. Kristensen Soni, S.J. Till, and S.R. Durham Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy J Allergy Clin Immunol 112 2003 915 922
26. S.R. Durham, H.J. Gould, and Q.A. Hamid Local IgE production in nasal allergy Int Arch Allergy Immunol 113 1997 128 130